Javier Blanco-Blanco
Research Subjects
Research Interests
Javier Blanco-Blanco has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Irene Simón
Ingulados, S.L., 10004 Cáceres, Spain
1 shared publication - María Bravo
INGULADOS SL Miguel Servet 11‐13 Cáceres, Extremadura Spain
1 shared publication - María Coronada Fernández-Calderón
Department of Biomedical Science, Area of Microbiology, University of Extremadura, 06006 Badajoz, Spain
1 shared publication - Miguel Fajardo-Olivares
Microbiology Department, University Hospital of Badajoz (HUB), 06080 Badajoz, Spain
1 shared publication - Pedro Fernández-Llario
Innovación en Gestión y Conservación de Ingulados S.L., 10004 Caceres, Spain
1 shared publication - Rosario Cerrato
Ingulados S.L., Calle Miguel Servet 13, 10003 Cáceres, Spain
1 shared publication
Latest Publications
- Open Access
- 20 February 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (3) , 200
Synergistic Activity of Ingulados Bacteria with Antibiotics against Multidrug-Resistant Pathogens
Antimicrobial resistance is a critical challenge due to the overuse of conventional antimicrobials, and alternative solutions are urgently needed. This study investigates the efficacy of compounds derived from lactic acid bacteria (LAB) fermentation combined with antibiotics against multidrug-resistant pathogens isolated from clinical cases in a hospital setting. Strains of Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium and faecalis were isolated and selected from blood, respiratory, and urine samples. They were tested against the fermentation products from the Ingulados LAB collection (BAL5, BAL6, BAL8, BAL13, and BAL16), recognized for their antimicrobial efficacy against veterinary pathogens. The activity against multidrug-resistant (MDR) pathogens was evaluated initially, followed by synergy tests using checkerboard assays and subsequent analysis. Bioinformatic assessments and supernatant treatments were performed to characterize the nature of the compounds responsible for the antimicrobial activity. Notably, BAL16 exhibited significant growth inhibition against multidrug-resistant E. faecium. Synergy tests highlighted its combined activity with tetracycline through FICI and surface analysis and bioinformatic analysis unveiled the protein fraction containing bacteriocins as the underlying mechanism. This study highlights BAL16 fermentation products potential as valuable antimicrobial agents against MDR E. faecium infections, attributed to bacteriocins. Further in-depth studies are necessary for complete bacteriocin characterization.
- 20 February 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (3) , 200
Open AccessSynergistic Activity of Ingulados Bacteria with Antibiotics against Multidrug-Resistant Pathogens
Antimicrobial resistance is a critical challenge due to the overuse of conventional antimicrobials, and alternative solutions are urgently needed. This study investigates the efficacy of compounds derived from lactic acid bacteria (LAB) fermentation combined with antibiotics against multidrug-resistant pathogens isolated from clinical cases in a hospital setting. Strains of Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium and faecalis were isolated and selected from blood, respiratory, and urine samples. They were tested against the fermentation products from the Ingulados LAB collection (BAL5, BAL6, BAL8, BAL13, and BAL16), recognized for their antimicrobial efficacy against veterinary pathogens. The activity against multidrug-resistant (MDR) pathogens was evaluated initially, followed by synergy tests using checkerboard assays and subsequent analysis. Bioinformatic assessments and supernatant treatments were performed to characterize the nature of the compounds responsible for the antimicrobial activity. Notably, BAL16 exhibited significant growth inhibition against multidrug-resistant E. faecium. Synergy tests highlighted its combined activity with tetracycline through FICI and surface analysis and bioinformatic analysis unveiled the protein fraction containing bacteriocins as the underlying mechanism. This study highlights BAL16 fermentation products potential as valuable antimicrobial agents against MDR E. faecium infections, attributed to bacteriocins. Further in-depth studies are necessary for complete bacteriocin characterization.